Jennifer E. Vela

1.5k total citations
19 papers, 1.2k citations indexed

About

Jennifer E. Vela is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Jennifer E. Vela has authored 19 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 10 papers in Virology and 8 papers in Molecular Biology. Recurrent topics in Jennifer E. Vela's work include HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (10 papers) and Biochemical and Molecular Research (8 papers). Jennifer E. Vela is often cited by papers focused on HIV/AIDS drug development and treatment (18 papers), HIV Research and Treatment (10 papers) and Biochemical and Molecular Research (8 papers). Jennifer E. Vela collaborates with scholars based in United States, United Kingdom and Sweden. Jennifer E. Vela's co-authors include Adrian S. Ray, Tomáš Cihlář, L. Tong, Michael D. Fuller, Gerry Rhodes, Eugene Eisenberg, Lijun Zhang, Geneviève Laflamme, Aesop Cho and Choung U. Kim and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of Hepatology and PLoS Pathogens.

In The Last Decade

Jennifer E. Vela

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer E. Vela United States 17 931 367 317 296 139 19 1.2k
Brian L. Robbins United States 21 1.1k 1.2× 654 1.8× 295 0.9× 397 1.3× 101 0.7× 43 1.4k
Katy H. P. Moore United States 16 745 0.8× 393 1.1× 117 0.4× 305 1.0× 147 1.1× 24 1.1k
P. L. Meenhorst Netherlands 19 682 0.7× 355 1.0× 187 0.6× 261 0.9× 107 0.8× 37 1.1k
Gabriel Birkuš United States 23 1.2k 1.3× 626 1.7× 572 1.8× 577 1.9× 194 1.4× 41 1.9k
Andrew Mulato United States 22 1.6k 1.7× 1.2k 3.3× 315 1.0× 586 2.0× 232 1.7× 33 2.1k
Gerry Rhodes United States 11 434 0.5× 273 0.7× 106 0.3× 145 0.5× 72 0.5× 21 709
Caroline E. Ridgway United Kingdom 12 948 1.0× 1.0k 2.8× 180 0.6× 233 0.8× 100 0.7× 12 1.4k
Bruno Marchand United States 24 1.2k 1.3× 975 2.7× 669 2.1× 409 1.4× 174 1.3× 41 1.9k
T Shirasaka United States 13 1.1k 1.1× 967 2.6× 260 0.8× 233 0.8× 71 0.5× 17 1.3k
Marshall W. Fordyce United States 16 1.5k 1.6× 955 2.6× 179 0.6× 443 1.5× 233 1.7× 30 1.8k

Countries citing papers authored by Jennifer E. Vela

Since Specialization
Citations

This map shows the geographic impact of Jennifer E. Vela's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer E. Vela with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer E. Vela more than expected).

Fields of papers citing papers by Jennifer E. Vela

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer E. Vela. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer E. Vela. The network helps show where Jennifer E. Vela may publish in the future.

Co-authorship network of co-authors of Jennifer E. Vela

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer E. Vela. A scholar is included among the top collaborators of Jennifer E. Vela based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer E. Vela. Jennifer E. Vela is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Murakami, Eisuke, Ting Wang, Darius Babusis, et al.. (2014). Metabolism and Pharmacokinetics of the Anti-Hepatitis C Virus Nucleotide Prodrug GS-6620. Antimicrobial Agents and Chemotherapy. 58(4). 1943–1951. 28 indexed citations
2.
Cho, Aesop, Oliver L. Saunders, Thomas Butler, et al.. (2012). Synthesis and antiviral activity of a series of 1′-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorganic & Medicinal Chemistry Letters. 22(8). 2705–2707. 156 indexed citations
3.
Arnold, Jamie J., Suresh D. Sharma, Joy Y. Feng, et al.. (2012). Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides. PLoS Pathogens. 8(11). e1003030–e1003030. 98 indexed citations
4.
Fenaux, Martijn, Guofeng Cheng, Eric Mabery, et al.. (2011). 1205 GS-6620, A NOVEL ANTI-HEPATITIS C VIRUS NUCLEOTIDE PRODRUG, HAS A HIGH BARRIER TO RESISTANCE IN VITRO. Journal of Hepatology. 54. S476–S476. 3 indexed citations
5.
Feng, Jianhua, Kum Thong Wong, L. Zhang, et al.. (2011). 1233 GS-6620: A LIVER TARGETED NUCLEOTIDE PRODRUG WITH POTENT PAN-GENOTYPE ANTI-HEPATITIS C VIRUS ACTIVITY IN VITRO. Journal of Hepatology. 54. S487–S487. 4 indexed citations
6.
Mackman, Richard L., Adrian S. Ray, Hon C. Hui, et al.. (2010). Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148. Bioorganic & Medicinal Chemistry. 18(10). 3606–3617. 49 indexed citations
7.
Rompay, Koen K. A. Van, et al.. (2009). Nucleotide Analogue Prodrug Tenofovir Disoproxil Enhances Lymphoid Cell Loading following Oral Administration in Monkeys. Molecular Pharmaceutics. 6(4). 1145–1151. 51 indexed citations
8.
Boojamra, Constantine G., Jay P. Parrish, David Sperandio, et al.. (2008). Design, synthesis, and anti-HIV activity of 4′-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry. 17(4). 1739–1746. 43 indexed citations
9.
Cihlář, Tomáš, Geneviève Laflamme, Robyn L. Fisher, et al.. (2008). Novel Nucleotide Human Immunodeficiency Virus Reverse Transcriptase Inhibitor GS-9148 with a Low Nephrotoxic Potential: Characterization of Renal Transport and Accumulation. Antimicrobial Agents and Chemotherapy. 53(1). 150–156. 45 indexed citations
10.
Vela, Jennifer E., Michael D. Miller, Gerald Rhodes, & Adrian S. Ray. (2008). Effect of Nucleoside and Nucleotide Reverse Transcriptase Inhibitors of HIV on Endogenous Nucleotide Pools. Antiviral Therapy. 13(6). 789–797. 16 indexed citations
11.
Cihlář, Tomáš, Adrian S. Ray, Geneviève Laflamme, et al.. (2007). Molecular Assessment of the Potential for Renal Drug Interactions between Tenofovir and HIV Protease Inhibitors. Antiviral Therapy. 12(2). 267–272. 83 indexed citations
12.
Mackman, Richard L., Constantine G. Boojamra, Lijun Zhang, et al.. (2007). Synthesis, anti-HIV activity, and resistance profiles of ribose modified nucleoside phosphonates. Bioorganic & Medicinal Chemistry Letters. 17(24). 6785–6789. 27 indexed citations
13.
Cihlář, Tomáš, Adrian S. Ray, Constantine G. Boojamra, et al.. (2007). Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131. Antimicrobial Agents and Chemotherapy. 52(2). 655–665. 75 indexed citations
14.
Ray, Adrian S., Jennifer E. Vela, Constantine G. Boojamra, et al.. (2007). Intracellular Metabolism of the Nucleotide Prodrug GS-9131, a Potent Anti-Human Immunodeficiency Virus Agent. Antimicrobial Agents and Chemotherapy. 52(2). 648–654. 42 indexed citations
15.
Ray, Adrian S., Tomáš Cihlář, L. Tong, et al.. (2006). Mechanism of Active Renal Tubular Efflux of Tenofovir. Antimicrobial Agents and Chemotherapy. 50(10). 3297–3304. 269 indexed citations
16.
Vela, Jennifer E., et al.. (2006). Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2′-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. Journal of Chromatography B. 848(2). 335–343. 51 indexed citations
17.
Borroto–Esoda, Katyna, Jennifer E. Vela, Florence Myrick, Adrian S. Ray, & Michael D. Miller. (2006). In Vitro Evaluation of the Anti-HIV Activity and Metabolic Interactions of Tenofovir and Emtricitabine. Antiviral Therapy. 11(3). 377–384. 57 indexed citations
18.
Ray, Adrian S., Florence Myrick, Jennifer E. Vela, et al.. (2005). Lack of a Metabolic and Antiviral Drug Interaction between Tenofovir, Abacavir and Lamivudine. Antiviral Therapy. 10(3). 451–457. 29 indexed citations
19.
Ray, Adrian S., et al.. (2004). Effective metabolism and long intracellular half life of the anti-Hepatitis B agent adefovir in hepatic cells. Biochemical Pharmacology. 68(9). 1825–1831. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian L. Robbins Breakdown of academic impact, for papers by Katy H. P. Moore Breakdown of academic impact, for papers by P. L. Meenhorst Breakdown of academic impact, for papers by Gabriel Birkuš Breakdown of academic impact, for papers by Andrew Mulato Breakdown of academic impact, for papers by Gerry Rhodes Breakdown of academic impact, for papers by Caroline E. Ridgway Breakdown of academic impact, for papers by Bruno Marchand Breakdown of academic impact, for papers by T Shirasaka Breakdown of academic impact, for papers by Marshall W. Fordyce
Rankless by CCL
2026